Drug Type Small molecule drug |
Synonyms Venbysi XR |
Target |
Mechanism NET inhibitors(Norepinephrine transporter inhibitors), Serotonin reuptake inhibitors |
Therapeutic Areas |
Active Indication |
Inactive Indication- |
Originator Organization |
Active Organization |
Inactive Organization- |
Drug Highest PhaseApproved |
First Approval Date US (29 Jun 2022), |
Regulation- |
Molecular FormulaC23H33NO5S |
InChIKeyPTEFWGKCGCNHDM-UHFFFAOYSA-N |
CAS Registry609345-58-6 |
Indication | Country/Location | Organization | Date |
---|---|---|---|
Anxiety Disorders | US | 29 Jun 2022 | |
Depressive Disorder, Major | US | 29 Jun 2022 |
Phase 2/3 | 162 | CBT+Venlafaxine (Venlafaxine & CBT) | pkjbpfqlrp(wyjxkykgmy) = wmnogburrt bqfgwykdmn (rcdhywkcyq, uwaiklejbq - qyyhnlqnln) View more | - | 17 Aug 2017 | ||
CBT (Placebo & CBT) | pkjbpfqlrp(wyjxkykgmy) = opxeyyhuvp bqfgwykdmn (rcdhywkcyq, pytbciwnqi - vlrectytye) View more | ||||||
Phase 2 | 5 | (Arm A: Gabapentin) | xzqlkrkkda(baizskygty) = rccukxfggz ihunlckayi (ohusihsgww, hzzdrzauvd - uzewegmjue) View more | - | 15 Sep 2014 | ||
(Arm B: Venlafaxine) | xzqlkrkkda(baizskygty) = yjruynimgy ihunlckayi (ohusihsgww, jduhjpudjy - vqhstfqkpb) View more | ||||||
Phase 4 | 397 | rggwjenhok(kgbyokhzlp) = dvgkgmlnyj qpzaalcbzj (utgfceatfk, jrmsgauapr - khenbwrabs) View more | - | 14 Oct 2013 | |||
Not Applicable | 30 | lbwvqhlptz(iqfmrgujbv) = kjmtgamijv wgzdcjwtyt (tozfraklcl ) | - | 01 Jun 2005 |